Tests the NeVa stent retriever to remove clots in people with stroke
Tests the NeVa stent retriever device to remove clots in adults with acute stroke.
Plain-language title generated from the registry record
Registry title: NeVa ONE Registry Study
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Niguarda HospitalMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vesalio
- Trial code
- NCT04562194
- Record updated
- 31 March 2026
- Original description
A prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.Read full original descriptionShow less
NEVA ONE One-Pass Reperfusion With the NeVa Stent-Retriever EMEA Registry
A prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
Inclusion: Only subjects already treated with the NeVa thrombectomy devices can be considered for enrollment; Age ≥18; NIHSS score ≥ 6; Pre-stroke mRS score ≤ 1; Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA; Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well [TLKW]); Imaging Inclusion Criteria:; The patient should have confirmed LVO and salvageable penumbra. Any automated software for determine the volume of viable tissue is acceptable. patient selection should follow the following guidelines:; ASPECTS 6-10 if treatment started 0-6 hours from TLKW; ASPECTS 8-10 if treatment started 6-24 hours from TLKW; Ischemic core ≤ 50 cc; Subject or legal representative is able and willing to give informed consent within 72 hours after the intervention (may use independent physician consent in this timeframe and gain subject or legal representative consent later than 72 hours).
Exclusion: Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept); Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration; Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories; History of severe allergy to contrast medium; Known allergy to NeVa materials (nitinol, stainless steel); Systemic infection; Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed; Cerebral vasculitis; Suspicion of aortic dissection, septic embolus, or bacterial endocarditis; Significant mass effect with midline shift; Evidence of intracranial tumor (except small meningioma); Inability to deploy NeVA device for at least one pass for any other reason; Life expectancy less than 6 months.